Molecular machineries of pH dysregulation in tumor microenvironment: Potential targets for cancer therapy

BioImpacts

Volumn 7, Issue 2, 2017, Pages 115-133

  Asgharzadeh, Mohammad Reza ^a   Barar, Jaleh ^b,c   Pourseif, Mohammad M ^b   Eskandani, Morteza ^b   Niya, Mojtaba Jafari ^a   Mashayekhi, Mohammad Reza ^d   Omidi, Yadollah ^b,c  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Cancer; Carbonic anhydrases; Hypoxia; PH dysregulation; Sodium hydrogen exchanger; Synthetic lethality; Targeted therapy of cancer; Tumor microenvironment; Vacuolar type H+ ATPase

Indexed keywords

5 (N ETHYL N ISOPROPYL)AMILORIDE; 5 (N,N DIMETHYL)AMILORIDE; AMILORIDE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; CARBONATE DEHYDRATASE XII; CARIPORIDE; GLUCOSE TRANSPORTER 1; MICRORNA; MONOCARBOXYLATE TRANSPORTER 1; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE INHIBITOR; SODIUM PROTON EXCHANGE PROTEIN 1;

ACIDIFICATION; ALKALINIZATION; ANOIKIS; APOPTOSIS; BIOENERGY; CANCER CELL; CANCER GROWTH; CANCER THERAPY; DRUG EFFECT; EPIGENETICS; EXTRACELLULAR FLUID; GENETIC VARIABILITY; GENETIC VARIATION; HUMAN; HYPOXIA; INTRACELLULAR FLUID; METABOLISM; METABOLITE; NONHUMAN; PH; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SOLID MALIGNANT NEOPLASM; TUMOR INVASION; TUMOR MICROENVIRONMENT;

EID: 85027460324     PISSN: 22285652     EISSN: 22285660     Source Type: Journal    
DOI: 10.15171/bi.2017.15     Document Type: Review

References (182)

1. Barar J, Omidi Y. Dysregulated pH in Tumor Microenvironment Checkmates Cancer Therapy. Bioimpacts 2013; 3: 149-62. doi:10. 5681/bi. 2013. 036
2. Webb BA, Chimenti M, Jacobson MP, Barber DL. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer 2011; 11: 671-7. doi:10. 1038/nrc3110
3. Busco G, Cardone RA, Greco MR, Bellizzi A, Colella M, Antelmi E, et al. NHE1 promotes invadopodial ECM proteolysis through acidification of the peri-invadopodial space. Faseb j 2010; 24: 3903-15 doi:10. 1096/fj. 09-149518
4. Amith SR, Fliegel L. Regulation of the Na+/H+ Exchanger (NHE1) in Breast Cancer Metastasis. Cancer Res 2013; 73: 1259-64. doi:10. 1158/0008-5472. can-12-4031
5. Lin Y, Chang G, Wang J, Jin W, Wang L, Li H, et al. NHE1 mediates MDA-MB-231 cells invasion through the regulation of MT1-MMP. Exp Cell Res 2011; 317: 2031-40. doi:10. 1016/j. yexcr. 2011. 05. 026
6. Daniel C, Bell C, Burton C, Harguindey S, Reshkin SJ, Rauch C. The role of proton dynamics in the development and maintenance of multidrug resistance in cancer. Biochim Biophys Acta 2013; 1832: 606-17. doi:10. 1016/j. bbadis. 2013. 01. 020
7. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005; 202(3): 654-62. doi: 10. 1002/jcp. 20166
8. Heinrich EL, Walser TC, Krysan K, Liclican EL, Grant JL, Rodriguez NL, et al. The inflammatory tumor microenvironment, epithelial mesenchymal transition and lung carcinogenesis. Cancer Microenviron 2012; 5: 5-18. doi:10. 1007/s12307-011-0089-0
9. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008; 13: 472-82. doi:10. 1016/j. ccr. 2008. 05. 005
10. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-33. doi:10. 1126/science. 1160809
11. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989; 8: 98-101
12. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453-8. doi:10. 1038/ nrc1098
13. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015; 348: 74-80. doi:10. 1126/ science. aaa6204
14. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci 2012; 125: 5591-6. doi:10. 1242/jcs. 116392
15. Romero-Garcia S, Moreno-Altamirano MMB, Prado-Garcia H, Sánchez-García FJ. Lactate contribution to the tumor microenvironment: Mechanisms, effects on immune cells and therapeutic relevance. Frontiers in Immunology 2016; 7. doi:10. 3389/fimmu. 2016. 00052
16. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancerrelated inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073-81. doi:10. 1093/ carcin/bgp127
17. Cramer DW, Finn OJ. Epidemiologic perspective on immunesurveillance in cancer. Curr Opin Immunol 2011; 23: 265-71. doi:10. 1016/j. coi. 2011. 01. 002
18. Tsai MJ, Chang WA, Huang MS, Kuo PL. Tumor microenvironment: a new treatment target for cancer. ISRN Biochem 2014; 2014: 3519 59 doi:10. 1155/2014/351959
19. Mao Y, Keller ET, Garfield DH, Shen K, Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 2013; 32: 303-15. doi:10. 1007/s10555-012-9415-3
20. Shain KH, Dalton WS. Environmental-mediated drug resistance: a target for multiple myeloma therapy. Expert Rev Hematol 2009; 2: 649-62. doi:10. 1586/ehm. 09. 55
21. Bierie B, Moses HL. TGF-beta and cancer. Cytokine Growth Factor Rev 2006; 17: 29-40. doi:10. 1016/j. cytogfr. 2005. 09. 006
22. Bigatto V, De Bacco F, Casanova E, Reato G, Lanzetti L, Isella C, et al. TNF-alpha promotes invasive growth through the MET signaling pathway. Mol Oncol 2015; 9: 377-88. doi:10. 1016/j. molonc. 2014. 09. 002
23. Martin NK, Gaffney EA, Gatenby RA, Maini PK. Tumour-stromal interactions in acid-mediated invasion: a mathematical model. J Theor Biol 2010; 267: 461-70. doi:10. 1016/j. jtbi. 2010. 08. 028
24. Matsuyama S, Llopis J, Deveraux QL, Tsien RY, Reed JC. Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat Cell Biol 2000; 2: 318-25. doi:10. 1038/35014006
25. Putney LK, Barber DL. Na-H exchange-dependent increase in intracellular pH times G2/M entry and transition. J Biol Chem 2003; 278: 44645-9. doi:10. 1074/jbc. M308099200
26. Detry B, Erpicum C, Paupert J, Blacher S, Maillard C, Bruyere F, et al. Matrix metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase. Blood 2012; 119: 5048-56. doi:10. 1182/blood-2011-12-400267
27. Noel A, Gutierrez-Fernandez A, Sounni NE, Behrendt N, Maquoi E, Lund IK, et al. New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. Front Pharmacol 2012; 3: 140. doi:10. 3389/fphar. 2012. 00140
28. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009; 139: 891-906. doi:10. 1016/j. cell. 2009. 10. 027
29. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007; 356: 227-36. doi:10. 1056/NEJMoa062790
30. Samuel MS, Lopez JI, McGhee EJ, Croft DR, Strachan D, Timpson P, et al. Actomyosin-mediated cellular tension drives increased tissue stiffness and beta-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell 2011; 19: 776-91. doi:10. 1016/j. ccr. 2011. 05. 008
31. Hynes RO. The extracellular matrix: not just pretty fibrils. Science 2009; 326: 1216-9. doi:10. 1126/science. 1176009
32. Jarvelainen H, Sainio A, Koulu M, Wight TN, Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 2009; 61: 198-223. doi:10. 1124/ pr. 109. 001289
33. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 1999; 17: 799-808
34. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, et al. The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol 2002; 187: 39-45
35. Georgiadis D, Yiotakis A. Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg Med Chem 2008; 16: 8781-94. doi:10. 1016/j. bmc. 2008. 08. 058
36. Lu X, Lu D, Scully M, Kakkar V. ADAM proteins-therapeutic potential in cancer. Curr Cancer Drug Targets 2008; 8: 720-32. doi: 10. 2174/156800908786733478
37. Fontanil T, Rua S, Llamazares M, Moncada-Pazos A, Quiros PM, Garcia-Suarez O, et al. Interaction between the ADAMTS-12 metalloprotease and fibulin-2 induces tumor-suppressive effects in breast cancer cells. Oncotarget 2014; 5: 1253-64. doi:10. 18632/ oncotarget. 1690
38. Mayorca-Guiliani A, Erler JT. The potential for targeting extracellular LOX proteins in human malignancy. Onco Targets Ther 2013; 6: 1729-35. doi:10. 2147/ott. s38110
39. Lentini A, Abbruzzese A, Provenzano B, Tabolacci C, Beninati S. Transglutaminases: key regulators of cancer metastasis. Amino Acids 2013; 44: 25-32. doi:10. 1007/s00726-012-1229-7
40. Dutta A, Li J, Lu H, Akech J, Pratap J, Wang T, et al. Integrin alphavbeta6 promotes an osteolytic program in cancer cells by upregulating MMP2. Cancer Res 2014; 74: 1598-608. doi:10. 1158/0008-5472. can-13-1796
41. Craig EA, Parker P, Camenisch TD. Size-dependent regulation of Snail2 by hyaluronan: its role in cellular invasion. Glycobiology 2009; 19: 890-8. doi:10. 1093/glycob/cwp064
42. Telmer PG, Tolg C, McCarthy JB, Turley EA. How does a protein with dual mitotic spindle and extracellular matrix receptor functions affect tumor susceptibility and progression? Commun Integr Biol 2011; 4: 182-5. doi:10. 4161/cib. 4. 2. 14270
43. Dicker KT, Gurski LA, Pradhan-Bhatt S, Witt RL, Farach-Carson MC, Jia X. Hyaluronan: a simple polysaccharide with diverse biological functions. Acta Biomater 2014; 10: 1558-70. doi:10. 1016/j. actbio. 2013. 12. 019
44. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol 1995; 130: 503-6. doi: 10. 1083/jcb. 130. 3. 503
45. Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 2002; 14: 608-16. doi: 10. 1016/S0955-0674(02)00361-7
46. Varga I, Hutoczki G, Szemcsak CD, Zahuczky G, Toth J, Adamecz Z, et al. Brevican, neurocan, tenascin-C and versican are mainly responsible for the invasiveness of low-grade astrocytoma. Pathol Oncol Res 2012; 18: 413-20. doi:10. 1007/s12253-011-9461-0
47. Ye J, Wu D, Wu P, Chen Z, Huang J. The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment. Tumour Biol 2014; 35: 3945-51. doi:10. 1007/s13277-013-1561-x
48. S Skandalis S, J Aletras A, Gialeli C, D Theocharis A, Afratis N, N Tzanakakis G, et al. Targeting the tumor proteasome as a mechanism to control the synthesis and bioactivity of matrix macromolecules. Current molecular medicine 2012; 12: 1068-82. doi: 10. 2174/156652412802480943
49. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004; 14: 198-206. doi:10. 1016/j. semradonc. 2004. 04. 008
50. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000; 60: 2497-503
51. Olive PL, Durand RE. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev 1994; 13: 121-38
52. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999; 5: 662-8. doi:10. 1038/9511
53. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270: 1230-7
54. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989; 49: 4373-84
55. Guo YS, Jin GF, Houston CW, Thompson JC, Townsend CM, Jr. Insulin-like growth factor-I promotes multidrug resistance in MCLM colon cancer cells. J Cell Physiol 1998; 175: 141-8 doi:10. 1002/(sici)1097-4652(199805)175:2<141::aidjcp3> 3. 0. co;2-o
56. Eskandani M, Vandghanooni S, Barar J, Nazemiyeh H, Omidi Y. Cell physiology regulation by hypoxia inducible factor-1: Targeting oxygen-related nanomachineries of hypoxic cells. Int J Biol Macromol 2017; 99: 46-62. doi:10. 1016/j. ijbiomac. 2016. 10. 113
57. Tomida A, Tsuruo T. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des 1999; 14: 169-77
58. Gray MD, Mann M, Nitiss JL, Hendershot LM. Activation of the unfolded protein response is necessary and sufficient for reducing topoisomerase IIalpha protein levels and decreasing sensitivity to topoisomerase-targeted drugs. Mol Pharmacol 2005; 68: 1699-707. doi:10. 1124/mol. 105. 014753
59. Omidi Y, Barar J. Targeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines. Bioimpacts 2014; 4: 55-67. doi:10. 5681/bi. 2014. 021
60. Rafi MA, Omidi Y. A prospective highlight on exosomal nanoshuttles and cancer immunotherapy and vaccination. Bioimpacts 2015; 5: 117-22. doi:10. 15171/bi. 2015. 22
61. Cowan DS, Tannock IF. Factors that influence the penetration of methotrexate through solid tissue. Int J Cancer 2001; 91: 120-5
62. Gerweck LE, Vijayappa S, Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol Cancer Ther 2006; 5: 1275-9. doi:10. 1158/1535-7163. mct-06-0024
63. Sun Y. Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures. Med Res Rev 2015; 35: 408-36. doi:10. 1002/med. 21338
64. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13: 714-26. doi:10. 1038/nrc3599
65. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 2011; 25: 2465-79. doi:10. 1101/gad. 180331. 111
66. Williams RT, den Besten W, Sherr CJ. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes Dev 2007; 21: 2283-7. doi:10. 1101/gad. 1588607
67. Lee JK, Joo KM, Lee J, Yoon Y, Nam DH. Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling. Onco Targets Ther 2014; 7: 1933-44. doi:10. 2147/ ott. s36582
68. Shostak K, Zhang X, Hubert P, Goktuna SI, Jiang Z, Klevernic I, et al. NF-kappaB-induced KIAA1199 promotes survival through EGFR signalling. Nat Commun 2014; 5: 5232. doi:10. 1038/ ncomms6232
69. Rosano L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Caprara V, et al. Endothelin A receptor/beta-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy. Cancer Res 2014; 74: 7453-64. doi:10. 1158/0008-5472. can-13-3133
70. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487: 505-9. doi:10. 1038/ nature11249
71. Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, Murphy JM, et al. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 2007; 13: 5020-7. doi:10. 1158/1078-0432. ccr-07-0731
72. Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM, et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell 2011; 20: 370-83. doi:10. 1016/j. ccr. 2011. 08. 010
73. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006; 116: 1955-62 doi:10. 1172/jci26532
74. Sounni NE, Noel A. Targeting the tumor microenvironment for cancer therapy. Clin Chem 2013; 59: 85-93. doi: 10. 1373/ clinchem. 2012. 185363
75. Jeschke J, Collignon E, Fuks F. DNA methylome profiling beyond promoters-taking an epigenetic snapshot of the breast tumor microenvironment. Febs J 2015; 282: 1801-14. doi:10. 1111/ febs. 13125. doi:10. 1111/ febs. 13125
76. Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y, et al. New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med 2015; 13: 45. doi:10. 1186/s12916-015-0278-7
77. Harguindey S, Arranz JL, Polo Orozco JD, Rauch C, Fais S, Cardone RA, et al. Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs-an integral molecular/ biochemical/metabolic/clinical approach after one hundred years of cancer research. J Transl Med 2013; 11: 282. doi:10. 1186/1479-5876-11-282
78. Orlowski J, Grinstein S. Diversity of the mammalian sodium/ proton exchanger SLC9 gene family. Pflugers Arch 2004; 447: 549-62 doi:10. 1007/s00424-003-1110-3
79. Wakabayashi S, Ikeda T, Iwamoto T, Pouyssegur J, Shigekawa M. Calmodulin-binding autoinhibitory domain controls "pHsensing" in the Na+/H+ exchanger NHE1 through sequencespecific interaction. Biochemistry 1997; 36: 12854-61. doi:10. 1021/ bi9715472
80. Grinstein S, Woodside M, Waddell TK, Downey GP, Orlowski J, Pouyssegur J, et al. Focal localization of the NHE-1 isoform of the Na+/H+ antiport: assessment of effects on intracellular pH. Embo j 1993; 12: 5209-18
81. Biemesderfer D, Reilly RF, Exner M, Igarashi P, Aronson PS. Immunocytochemical characterization of Na(+)-H+ exchanger isoform NHE-1 in rabbit kidney. Am J Physiol 1992; 263: F833-40
82. Petrecca K, Atanasiu R, Grinstein S, Orlowski J, Shrier A. Subcellular localization of the Na+/H+ exchanger NHE1 in rat myocardium. Am J Physiol 1999; 276: H709-17
83. Malo ME, Fliegel L. Physiological role and regulation of the Na+/H+ exchanger. Can J Physiol Pharmacol 2006; 84: 1081-95. doi:10. 1139/y06-065
84. Putney LK, Denker SP, Barber DL. The changing face of the Na+/ H+ exchanger, NHE1: structure, regulation, and cellular actions. Annu Rev Pharmacol Toxicol 2002; 42: 527-52. doi:10. 1146/ annurev. pharmtox. 42. 092001. 143801
85. Tominaga T, Ishizaki T, Narumiya S, Barber DL. p160ROCK mediates RhoA activation of Na-H exchange. Embo j 1998; 17: 4712-22. doi:10. 1093/emboj/17. 16. 4712
86. Khaled AR, Moor AN, Li A, Kim K, Ferris DK, Muegge K, et al. Trophic factor withdrawal: p38 mitogen-activated protein kinase activates NHE1, which induces intracellular alkalinization. Mol Cell Biol 2001; 21: 7545-57. doi:10. 1128/mcb. 21. 22. 7545-7557. 2001
87. Matsushita M, Tanaka H, Mitsui K, Kanazawa H. Dual functional significance of calcineurin homologous protein 1 binding to Na(+)/H(+) exchanger isoform 1. Am J Physiol Cell Physiol 2011; 301: C280-8. doi:10. 1152/ajpcell. 00404. 2010
88. Pang T, Wakabayashi S, Shigekawa M. Expression of calcineurin B homologous protein 2 protects serum deprivation-induced cell death by serum-independent activation of Na+/H+ exchanger. J Biol Chem 2002; 277: 43771-7. doi:10. 1074/jbc. M208313200
89. Li QH, Wang LH, Lin YN, Chang GQ, Li HW, Jin WN, et al. Nuclear accumulation of calcineurin B homologous protein 2 (CHP2) results in enhanced proliferation of tumor cells. Genes Cells 2011; 16: 416-26. doi:10. 1111/j. 1365-2443. 2011. 01497. x
90. Li X, Liu Y, Kay CM, Muller-Esterl W, Fliegel L. The Na+/H+ exchanger cytoplasmic tail: structure, function, and interactions with tescalcin. Biochemistry 2003; 42: 7448-56. doi:10. 1021/ bi027143d
91. Aharonovitz O, Zaun HC, Balla T, York JD, Orlowski J, Grinstein S. Intracellular pH regulation by Na(+)/H(+) exchange requires phosphatidylinositol 4, 5-bisphosphate. J Cell Biol 2000; 150: 213-24
92. Li X, Liu Y, Alvarez BV, Casey JR, Fliegel L. A novel carbonic anhydrase II binding site regulates NHE1 activity. Biochemistry 2006; 45: 2414-24. doi:10. 1021/bi051132d
93. Denker SP, Huang DC, Orlowski J, Furthmayr H, Barber DL. Direct binding of the Na-H exchanger NHE1 to ERM proteins regulates the cortical cytoskeleton and cell shape independently of H(+) translocation. Mol Cell 2000; 6: 1425-36. doi: 10. 1016/S1097-2765(00)00139-8
94. Silva NL, Haworth RS, Singh D, Fliegel L. The carboxyl-terminal region of the Na+/H+ exchanger interacts with mammalian heat shock protein. Biochemistry 1995; 34: 10412-20
95. Lehoux S, Abe J, Florian JA, Berk BC. 14-3-3 Binding to Na+/ H+ exchanger isoform-1 is associated with serum-dependent activation of Na+/H+ exchange. J Biol Chem 2001; 276: 15794-800. doi:10. 1074/jbc. M100410200
96. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92. doi:10. 1056/nejm200103153441101
97. Jin W, Li Q, Wang J, Chang G, Lin Y, Li H, et al. Na+/H+ exchanger 1 inhibition contributes to K562 leukaemic cell differentiation. Cell Biol Int 2012; 36: 739-45. doi:10. 1042/cbi20100919
98. Spugnini EP, Sonveaux P, Stock C, Perez-Sayans M, De Milito A, Avnet S, et al. Proton channels and exchangers in cancer. Biochimica et Biophysica Acta (BBA)-Biomembranes 2014
99. Lv C, Yang X, Yu B, Ma Q, Liu B, Liu Y. Blocking the Na+/H+ exchanger 1 with cariporide (HOE642) reduces the hypoxiainduced invasion of human tongue squamous cell carcinoma. Int J Oral Maxillofac Surg 2012; 41: 1206-10. doi:10. 1016/j. ijom. 2012. 03. 001
100. Wakabayashi S, Hisamitsu T, Pang T, Shigekawa M. Mutations of Arg440 and Gly455/Gly456 oppositely change pH sensing of Na+/ H+ exchanger 1. J Biol Chem 2003; 278: 11828-35. doi:10. 1074/jbc. M213243200
101. Lifton RP, Hunt SC, Williams RR, Pouyssegur J, Lalouel JM. Exclusion of the Na(+)-H+ antiporter as a candidate gene in human essential hypertension. Hypertension 1991; 17: 8-14
102. Cotter K, Stransky L, McGuire C, Forgac M. Recent Insights into the Structure, Regulation, and Function of the V-ATPases. Trends Biochem Sci 2015; 40: 611-22. doi: 10. 1016/j. tibs. 2015. 08. 005
103. Nelson N. Structure and function of V-ATPases in endocytic and secretory organelles. J Exp Biol1992; 172: 149-53
104. Izumi H, Torigoe T, Ishiguchi H, Uramoto H, Yoshida Y, Tanabe M, et al. Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev 2003; 29: 541-9. doi: 10. 1016/S0305-7372(03)00106-3
105. O'Callaghan KM, Ayllon V, O'Keeffe J, Wang Y, Cox OT, Loughran G, et al. Heme-binding protein HRG-1 is induced by insulin-like growth factor I and associates with the vacuolar H+-ATPase to control endosomal pH and receptor trafficking. J Biol Chem 2010; 285: 381-91. doi: 10. 1074/jbc. M109. 063248
106. Peña-Llopis S, Vega-Rubin-de-Celis S, Schwartz JC, Wolff NC, Tran TAT, Zou L, et al. Regulation of TFEB and V-ATPases by mTORC1. EMBO J 2011; 30: 3242-58. doi: 10. 1038/emboj. 2011. 257
107. Graham RM, Thompson JW, Webster KA. Inhibition of the vacuolar ATPase induces Bnip3-dependent death of cancer cells and a reduction in tumor burden and metastasis. Oncotarget 2014; 5: 1162. doi: 10. 18632/oncotarget. 1699
108. von Schwarzenberg K, Wiedmann RM, Oak P, Schulz S, Zischka H, Wanner G, et al. Mode of cell death induction by pharmacological vacuolar H+-ATPase (V-ATPase) inhibition. J Biol Chem 2013; 288: 1385-96. doi: 10. 1074/jbc. M112. 412007
109. Toyomura T, Oka T, Yamaguchi C, Wada Y, Futai M. Three subunit a isoforms of mouse vacuolar H(+)-ATPase. Preferential expression of the a3 isoform during osteoclast differentiation. J Biol Chem 2000; 275: 8760-5. doi: 10. 1074/jbc. 275. 12. 8760. doi: 10. 1074/jbc. 275. 12. 8760
110. Smith AN, Skaug J, Choate KA, Nayir A, Bakkaloglu A, Ozen S, et al. Mutations in ATP6N1B, encoding a new kidney vacuolar proton pump 116-kD subunit, cause recessive distal renal tubular acidosis with preserved hearing. Nat Genet 2000; 26: 71-5. doi: 10. 1038/79208
111. Cotter K, Capecci J, Sennoune S, Huss M, Maier M, Martinez-Zaguilan R, et al. Activity of Plasma Membrane V-ATPases Is Critical for the Invasion of MDA-MB231 Breast Cancer Cells. J Biol Chem. 2015;290(6):3680-92. doi: 10. 1074/jbc. M114. 611210
112. Chung C, Mader CC, Schmitz JC, Atladottir J, Fitchev P, Cornwell ML, et al. The vacuolar-ATPase modulates matrix metalloproteinase isoforms in human pancreatic cancer. Lab Invest. 2011;91(5):732-62 doi: 10. 1038/labinvest. 2011. 8
113. Nishisho T, Hata K, Nakanishi M, Morita Y, Sun-Wada G-H, Wada Y, et al. The a3 isoform vacuolar type H+-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Mol Cancer Res. 2011; 9: 845-55. doi: 10. 1158/1541-7786. MCR-10-0449
114. 114. Hendrix A, Sormunen R, Westbroek W, Lambein K, Denys H, Sys G, et al. Vacuolar H+ ATPase expression and activity is required for Rab27B-dependent invasive growth and metastasis of breast cancer. Int J Cancer. 2013; 133: 843-54. doi: 10. 1002/ijc. 28079
115. Gocheva V, Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell cycle 2007; 6: 60-4. doi: 10. 4161/cc. 6. 1. 3669
116. Gondi CS, Rao JS. Cathepsin B as a cancer target. Expert Opin Ther Targets. 2013; 17: 281-91. doi: 10. 1517/14728222. 2013. 740461
117. Lozupone F, Borghi M, Marzoli F, Azzarito T, Matarrese P, Iessi E, et al. TM9SF4 is a novel V-ATPase-interacting protein that modulates tumor pH alterations associated with drug resistance and invasiveness of colon cancer cells. Oncogene. 2015;34(40):5163-74 doi: 10. 1038/onc. 2014. 437
118. Schempp CM, von Schwarzenberg K, Schreiner L, Kubisch R, Müller R, Wagner E, et al. V-ATPase inhibition regulates anoikis resistance and metastasis of cancer cells. Mol Cancer Ther. 2014; 13: 926-37. doi: 10. 1158/1535-7163
119. Meo-Evoli N, Almacellas E, Massucci FA, Gentilella A, Ambrosio S, Kozma SC, et al. V-ATPase: a master effector of E2F1-mediated lysosomal trafficking, mTORC1 activation and autophagy. Oncotarget 2015; 6: 28057-70. doi: 10. 18632/oncotarget. 4812
120. Wiedmann RM, von Schwarzenberg K, Palamidessi A, Schreiner L, Kubisch R, Liebl J, et al. The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1. Cancer res 2012; 72: 5976-87. doi: 10. 1158/0008-5472. CAN-12-1772
121. Fan S-h, Wang Y-y, Wu Z-y, Zhang Z-f, Lu J, Li M-q, et al. AGPAT9 suppresses cell growth, invasion and metastasis by counteracting acidic tumor microenvironment through KLF4/LASS2/V-ATPase signaling pathway in breast cancer. Oncotarget 2015; 6: 18406. doi:10. 18632/oncotarget. 4074
122. Pérez-Sayáns M, García-García A, Reboiras-López MD, Gándara-Vila P. Role of V-ATPases in solid tumors: importance of the subunit C (Review). Int J Oncol 2009; 34: 1513-20. doi. org/10. 3892/ ijo_00000280
123. Muroi M, Shiragami N, Nagao K, Yamasaki M, Takatsuki A. Folimycin (concanamycin A), a specific inhibitor of V-ATPase, blocks intracellular translocation of the glycoprotein of vesicular stomatitis virus before arrival to the Golgi apparatus. Cell Struct Funct 1993; 18: 139-49. doi. org/10. 1247/csf. 18. 139
124. Menche D, Hassfeld J, Sasse F, Huss M, Wieczorek H. Design, synthesis, and biological evaluation of novel analogues of archazolid: a highly potent simplified V-ATPase inhibitor. Bioorg Med Chem Lett 2007; 17: 1732-5. doi:10. 1016/j. bmcl. 2006. 12. 073
125. Pérez-Sayáns M, Somoza-Martín JM, Barros-Angueira F, Rey JMG, García-García A. V-ATPase inhibitors and implication in cancer treatment. Cancer Treat Rev 2009; 35: 707-13. doi: 10. 1016/j. ctrv. 2009. 08. 003
126. Sennoune SR, Bakunts K, Martinez GM, Chua-Tuan JL, Kebir Y, Attaya MN, et al. Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol 2004; 286: C1443-C52. doi:10. 1152/ajpcell. 00407. 2003
127. Nakashima S, Hiraku Y, Tada-Oikawa S, Hishita T, Gabazza EC, Tamaki S, et al. Vacuolar H+-ATPase inhibitor induces apoptosis via lysosomal dysfunction in the human gastric cancer cell line MKN-1. J Biochem 2003; 134: 359-64. doi. org/10. 1093/jb/mvg153
128. Hishita T, Tada-Oikawa S, Tohyama K, Miura Y, Nishihara T, Tohyama Y, et al. Caspase-3 activation by lysosomal enzymes in cytochrome c-independent apoptosis in myelodysplastic syndrome-derived cell line P39. Cancer Res 2001; 61: 2878-84. doi: Published April 2001
129. Zhitomirsky B, Assaraf YG. Lysosomes as mediators of drug resistance in cancer. Drug Resist Updat 2016; 24: 23-33. doi: 10. 1016/j. drup. 2015. 11. 004
130. Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011; 10: 767-77. doi: 10. 1038/nrd3554
131. Ferry JG. The γ class of carbonic anhydrases. Biochim Biophys Acta 2010; 1804: 374-81. doi: 10. 1016/j. bbapap. 2009. 08. 026
132. Thiry A, Dogne J-M, Masereel B, Supuran CT. Targeting tumorassociated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 2006; 27: 566-73. doi:10. 1016/j. tips. 2006. 09. 002
133. Supuran C. Carbonic anhydrases: catalytic and inhibition mechanisms, distribuion and physiological roles. Carbonic Anhydrase: Its Inhibitors and Activators 2004; 1-23
134. Pastoreková S, Pastorek J. Cancer-related carbonic anhydrase isozymes and their inhibition. Carbonic Anhydrase-Its Inhibitors and Activators 2004; 253-80
135. Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010; 20: 3467-74. doi: 10. 1016/j. bmcl. 2010. 05. 009
136. Supuran CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med Chem 2011; 3: 1165-80. doi: 10. 4155/fmc. 11. 69
137. Švastová E, Huliiková A, Rafajová M, Zat'ovicová M, Gibadulinová A, Casini A, et al. Hypoxia activates the capacity of tumorassociated carbonic anhydrase IX to acidify extracellular pH. FEBS let 2004; 577: 439-45. doi:10. 1016/j. febslet. 2004. 10. 043
138. Maresca A, Temperini C, Pochet L, Masereel B, Scozzafava A, Supuran CT. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem 2009; 53: 335-44. doi: 10. 1021/jm901287j
139. Pearson MA, Fabbro D. Targeting protein kinases in cancer therapy: a success? Expert Rev Anticancer Ther 2004;4(6):1113-24. doi:10. 1586/14737140. 4. 6. 1113
140. Parkkila S, Innocenti A, Kallio H, Hilvo M, Scozzafava A, Supuran CT. The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian a-carbonic anhydrase isoforms. Bioorg Med Chem Lett 2009; 19: 4102-6. doi: 10. 1016/j. bmcl. 2009. 06. 002
141. Chrastina A, Závada J, Parkkila S, Kaluz Š, Kaluzová M, Rajcáni J, et al. Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int J Cancer 2003; 105: 873-81. doi:10. 1002/ ijc. 11142
142. Siebels M, Rohrmann K, Oberneder R, Stahler M, Haseke N, Beck J, et al. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 2011; 29: 121-6. doi: 10. 1007/s00345-010-0570-2
143. Stiti M, Cecchi A, Rami M, Abdaoui M, Barragan-Montero V, Scozzafava A, et al. Carbonic anhydrase inhibitor coated gold nanoparticles selectively inhibit the tumor-associated isoform IX over the cytosolic isozymes I and II. J Am Chem Soc 2008; 130: 16130-1. doi: 10. 1021/ja805558k
144. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-76
145. Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res 2002; 8: 1284-91
146. Ashida S, Nishimori I, Tanimura M, Onishi S, Shuin T. Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma. J Cancer Res Clin Oncol 2002; 128: 561-8. doi:10. 1007/ s00432-002-0374-x
147. Alvarez BV, Vilas GL, Casey JR. Metabolon disruption: a mechanism that regulates bicarbonate transport. EMBO J 2005; 24: 2499-511. doi:10. 1038/sj. emboj. 7600736
148. Chiche J, Ilc K, Laferrière J, Trottier E, Dayan F, Mazure NM, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer res 2009; 69: 358-68. doi: 10. 1158/0008-5472. CAN-08-2470
149. Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer res 2011; 71: 3364-76. doi: 10. 1158/0008-5472. CAN-10-4261
150. McIntyre A, Patiar S, Wigfield S, Li J-l, Ledaki I, Turley H, et al. Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res 2012; 18: 3100-11. doi: 10. 1158/1078-0432
151. Dubois L, Peeters S, Lieuwes NG, Geusens N, Thiry A, Wigfield S, et al. Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol 2011; 99: 424-31. oi: 10. 1016/j. radonc. 2011. 05. 045
152. Stock C, Schwab A. Protons make tumor cells move like clockwork. Pflugers Arch 2009; 458: 981-92. doi: 10. 1007/s00424-009-0677-8
153. Axelson H, Fredlund E, Ovenberger M, Landberg G, Påhlman S, editors. Hypoxia-induced dedifferentiation of tumor cells-a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol 2005;16(4-5):554-63. doi:10. 1016/j. semcdb. 2005. 03. 007
154. Hjelmeland AB, Wu Q, Heddleston J, Choudhary G, MacSwords J, Lathia J, et al. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ 2011; 18: 829-40. doi: 10. 1038/cdd. 2010. 150
155. Fujiwara D, Kato K, Nohara S, Iwanuma Y, Kajiyama Y. The usefulness of three-dimensional cell culture in induction of cancer stem cells from esophageal squamous cell carcinoma cell lines. Biochem Biophys Res Commun 2013; 434: 773-8. doi: 10. 1016/j. bbrc. 2013. 04. 008
156. Sansone P, Storci G, Giovannini C, Pandolfi S, Pianetti S, Taffurelli M, et al. p66Shc/Notch-3 Interplay Controls Self-Renewal and Hypoxia Survival in Human Stem/Progenitor Cells of the Mammary Gland Expanded In Vitro as Mammospheres. Stem Cells 2007; 25: 807-15. doi:10. 1634/stemcells. 2006-0442
157. Storci G, Sansone P, Trere D, Tavolari S, Taffurelli M, Ceccarelli C, et al. The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J Pathol 2008; 214: 25-37. doi:10. 1002/ path. 2254
158. Fiaschi T, Giannoni E, Taddei L, Cirri P, Marini A, Pintus G, et al. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle 2013; 12: 1791-801. doi: 10. 4161/cc. 24902
159. Csaderova L, Debreova M, Radvak P, Stano M, Vrestiakova M, Kopacek J, et al. The effect of carbonic anhydrase IX on focal contacts during cell spreading and migration. Front Physiol 2013; 4: 10. 3389. doi: 10. 3389/fphys. 2013. 00271
160. Švastová E, Žilka N, Zat'ovicová M, Gibadulinová A, Ciampor F, Pastorek J, et al. Carbonic anhydrase IX reduces E-cadherinmediated adhesion of MDCK cells via interaction with β-catenin. Exp Cell Res 2003; 290: 332-45. doi. org/10. 1016/S0014-4827(03)00351-3
161. Dorai T, Sawczuk IS, Pastorek J, Wiernik PH, Dutcher JP. The role of carbonic anhydrase IX overexpression in kidney cancer. Exp Cell Res 2005; 41: 2935-47. doi. org/10. 1016/S0014-4827(03)00351-3
162. Wiesener MS, Münchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1a in clear cell renal carcinomas. Cancer res 2001; 61: 5215-22
163. Sennoune SR, Bakunts K, Martínez GM, Chua-Tuan JL, Kebir Y, Attaya MN, et al. Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol 2004; 286: C1443-C52. doi:10. 1152/ajpcell. 00407. 2003
164. Gorbatenko A, Olesen CW, Boedtkjer E, Pedersen SF. Regulation and roles of bicarbonate transporters in cancer. Front Physiol 2013; 5: 130. doi: 10. 3389/fphys. 2014. 00130
165. Shakoori Z, Ghanbari H, Omidi Y, Pashaiasl M, Akbarzadeh A, Jomeh Farsangi Z, et al. Fluorescent multi-responsive cross-linked P(N-isopropylacrylamide)-based nanocomposites for cisplatin delivery. Drug Dev Ind Pharm 2017; 43: 1283-91. doi:10. 1080/03 639045. 2017. 1313859
166. Rahmanian N, Eskandani M, Barar J, Omidi Y. Recent trends in targeted therapy of cancer using graphene oxide-modified multifunctional nanomedicines. J Drug Target 2017; 25: 202-15. do i:10. 1080/1061186X. 2016. 1238475
167. Bakhtiary Z, Barar J, Aghanejad A, Saei AA, Nemati E, Ezzati Nazhad Dolatabadi J, et al. Microparticles containing erlotinibloaded solid lipid nanoparticles for treatment of non-small cell lung cancer. Drug Dev Ind Pharm 2017; 43: 1244-53. doi:10. 1080 /03639045. 2017. 1310223
168. Same S, Aghanejad A, Akbari Nakhjavani S, Barar J, Omidi Y. Radiolabeled theranostics: magnetic and gold nanoparticles. Bioimpacts 2016; 6: 169-81. doi:10. 15171/bi. 2016. 23
169. Johari-Ahar M, Barar J, Alizadeh AM, Davaran S, Omidi Y, Rashidi MR. Methotrexate-conjugated quantum dots: synthesis, characterisation and cytotoxicity in drug resistant cancer cells. J Drug Target 2016; 24: 120-33. doi:10. 3109/1061186X. 2015. 1058801
170. Azhdarzadeh M, Atyabi F, Saei AA, Varnamkhasti BS, Omidi Y, Fateh M, et al. Theranostic MUC-1 aptamer targeted gold coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging and photothermal therapy of colon cancer. Colloids Surf B Biointerfaces 2016; 143: 224-32. doi:10. 1016/j. colsurfb. 2016. 02. 058
171. Barar J, Kafil V, Majd MH, Barzegari A, Khani S, Johari-Ahar M, et al. Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells. J Nanobiotechnology 2015; 13: 26. doi:10. 1186/ s12951-015-0083-7
172. Matthaiou EI, Barar J, Sandaltzopoulos R, Li C, Coukos G, Omidi Y. Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer. Int J Nanomedicine 2014; 9: 1855-70. doi:10. 2147/IJN. S51880
173. Mashinchian O, Johari-Ahar M, Ghaemi B, Rashidi M, Barar J, Omidi Y. Impacts of quantum dots in molecular detection and bioimaging of cancer. Bioimpacts 2014; 4: 149-66. doi:10. 15171/ bi. 2014. 008
174. Barar J, Omidi Y. Surface modified multifunctional nanomedicines for simultaneous imaging and therapy of cancer. Bioimpacts 2014; 4: 3-14. doi:10. 5681/bi. 2014. 011
175. Tohidkia MR, Asadi F, Barar J, Omidi Y. Selection of potential therapeutic human single-chain Fv antibodies against cholecystokinin-B/gastrin receptor by phage display technology. BioDrugs 2013; 27: 55-67. doi:10. 1007/s40259-012-0007-0
176. Najar AG, Pashaei-Asl R, Omidi Y, Farajnia S, Nourazarian AR. EGFR antisense oligonucleotides encapsulated with nanoparticles decrease EGFR, MAPK1 and STAT5 expression in a human colon cancer cell line. Asian Pac J Cancer Prev 2013; 14: 495-8
177. Heidari Majd M, Asgari D, Barar J, Valizadeh H, Kafil V, Abadpour A, et al. Tamoxifen loaded folic acid armed PEGylated magnetic nanoparticles for targeted imaging and therapy of cancer. Colloids Surf B Biointerfaces 2013; 106: 117-25. doi:10. 1016/j. colsurfb. 2013. 01. 051
178. Barar J, Omidi Y. Targeted Gene Therapy of Cancer: Second Amendment toward Holistic Therapy. Bioimpacts 2013; 3: 49-51. doi:10. 5681/bi. 2013. 014
179. Khosroushahi AY, Naderi-Manesh H, Yeganeh H, Barar J, Omidi Y. Novel water-soluble polyurethane nanomicelles for cancer chemotherapy: physicochemical characterization and cellular activities. J Nanobiotechnology 2012; 10: 2. doi:10. 1186/1477-3155-10-2
180. Omidi Y. Smart multifunctional theranostics: simultaneous diagnosis and therapy of cancer. Bioimpacts 2011; 1: 145-7. doi:10. 5681/bi. 2011. 019
181. Nakhlband A, Barar J, Bidmeshkipour A, Heidari HR, Omidi Y. Bioimpacts of anti epidermal growth factor receptor antisense complexed with polyamidoamine dendrimers in human lung epithelial adenocarcinoma cells. J Biomed Nanotechnol 2010; 6: 360-9
182. Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. Hum Antibodies 2009; 18: 81-100. doi:10. 3233/HAB-2009-0204